INVESTORS

2015 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/01/15Enumeral to Present at the Oppenheimer 26th Annual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 1, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 26th Annual Healthcare C... 
Printer Friendly Version
11/18/15Enumeral Reports That Its Novel Class of Potentially Allosteric Anti-PD-1 Antibodies Can Elicit an Additive Effect on T Cell Activation in Ex Vivo Human Assays When Used in Combination with a Currently Marketed Anti-PD-1 Antibody
Assays Performed Using Lung Biopsy-Derived Tumor Infiltrating Lymphocytes Also Show That Correlates of Responsiveness May Include Expression Levels of the Checkpoint Protein TIM-3 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 18, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer an... 
Printer Friendly Version
11/10/15Enumeral Reports Third Quarter 2015 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended September 30, 2015. “We continue to make important progress in our research and development activities,... 
Printer Friendly Version
11/03/15Enumeral Reports That Its Novel Class of Anti-PD-1 Antibodies Elicits Higher T Cell Activation in Ex Vivo Human Assays than Currently Marketed Anti-PD-1 Antibodies
Assays Performed Using Lung Biopsy-Derived Tumor Infiltrating Lymphocytes Show Improved Restoration of T Cell Function Using Enumeral’s Anti-PD-1 Antibody CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 3, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in i... 
Printer Friendly Version
10/05/15Enumeral to Present at the Emerging Concepts in Host Response to Cancer Symposium at The University of Texas MD Anderson Cancer Center
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 5, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that the company will present a poster titled “Human Tumor-Based Identification of Immune Checkpoint Targets” at The University of Texas MD Anderson Cancer Center’s Emerging Concepts in ... 
Printer Friendly Version
09/24/15Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action
Provides Update on Additional Antibody Programs Against TIM-3 and LAG-3 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 24, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral also provided an update on the progress of... 
Printer Friendly Version
09/11/15Enumeral to Present at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference and BioPharm America 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 11, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Enumeral will present a poster titled “Human Tumor-Based Identification of Immune Checkpoint Targets” at the International Cancer Immunotherapy Conference. Enumeral’s poster will ... 
Printer Friendly Version
09/08/15Enumeral Achieves First Milestone in Merck Collaboration
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 8, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it has achieved the first milestone in its immuno-oncology-focused collaboration with Merck Sharp & Dohme Corp. (Merck). In this collaboration, the parties are applying Enumeral’s Human Approach immune profiling technology to colorectal cancer patient tissues in order to identify functional cellular responses to immuno-oncology ther... 
Printer Friendly Version
08/26/15Enumeral and UMass Medical School Enter Into Research Study Agreement
Study to Obtain Blood and Tissue Samples from Subjects Being Treated With Yervoy For the Treatment of Melanoma CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 26, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it has entered into a research study agreement with University of Massachusetts Medical School (UMMS), which includes that institution’s clinical partner, UMass Memorial Health Care, Inc. Pursuant to the study ... 
Printer Friendly Version
08/12/15Enumeral Reports Second Quarter 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 12, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended June 30, 2015. “We are pleased with the recent progress we have made in our pipeline, especially with ou... 
Printer Friendly Version
07/30/15Enumeral Appoints Robert J. Easton to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 30, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it has appointed Robert J. Easton to its Board of Directors. Mr. Easton is a recognized leader in the life sciences and healthcare industries, having led strategy development and supervised opportunity assessments for hundreds of clients across the globe, including large and specialty pharmaceutical companies, early-stage and publicly ... 
Printer Friendly Version
07/14/15Enumeral Announces Progress in PD-1, TIM-3 and Other Pipeline Programs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 14, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company’s R&D pipeline, including its TIM-3 antibody program. Enumeral has identified antibodies that appear to bind to PD-1 in a manner different from that of currently marketed anti-PD1 antibodies, ... 
Printer Friendly Version
07/01/15Enumeral to Participate in Immuno-Oncology Panel at the Cantor Fitzgerald Inaugural Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 1, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer of Enumeral, will participate in a panel discussion, titled “Continued Opportunities in Immuno-Oncology; Exploring Next-Generation Checkpoint Inhibition,” at the Cantor Fitzgerald Inaugural Healthcare Conference, to be held at Le Parker Meridien Hotel in New York City ... 
Printer Friendly Version
06/04/15Enumeral Expands Scientific Advisory Board to Support Development of Novel Immunomodulators
Dr. Giulio Draetta, of M.D. Anderson Cancer Center, and Dr. Kai Wucherpfennig, of Dana-Farber Cancer Institute, Appointed to Scientific Advisory Board CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Giulio Draetta, M.D., Ph.D., and Kai Wucherpfennig, M.D., Ph.D., recognized leaders in the fields of tu... 
Printer Friendly Version
05/15/15Enumeral Reports First Quarter 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended March 31, 2015. “During the first quarter, we further executed on our corporate strategy and continued t... 
Printer Friendly Version
03/19/15Enumeral Reports Fourth Quarter and Year-End 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 19, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months and full year ended December 31, 2014. “In the fourth quarter we continued to execute on our corporate st... 
Printer Friendly Version
03/17/15Enumeral to Present Corporate and Program Overview at March Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 17, 2015-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present a corporate overview at BioCentury’s 22nd Annual Future Leaders in the Biotech Industry conference on March 20, 2015 at 4:00 p.m. EDT. The presentation will be followed by a breakout session. The meeting is being held at the Millennium... 
Printer Friendly Version
02/23/15Enumeral Appoints Paul J. Sekhri to its Board of Directors
CAMBRIDGE, Mass.--February 23, 2015--Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today it appointed Paul J. Sekhri to its Board of Directors. Mr. Sekhri is an accomplished industry executive, with more than 25 years of experience in life sciences strategy, corporate development and corporate finance, having served in senior leadership positions at several pharmaceutical companies, including Novartis, Teva and Sanofi. He is currently President and Chief Executive Officer of Lycera... 
Printer Friendly Version
02/19/15Enumeral to Present at Sachs Associates Cancer Bio Partnering & Investment Forum
CAMBRIDGE, Mass.--February 19, 2015--Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present at the Sachs Associates Cancer Bio Partnering & Investment Forum on February 23, 2015 at 12:00 p.m. EST. The meeting is being held at the New York Academy of Sciences in New York City.A recording of the corporate presentation will be accessible on the Events page of Enumeral’s website followin... 
Printer Friendly Version
01/12/15Enumeral and Memorial Sloan Kettering Cancer Center to Research Cancer Immunology With Advanced Prototype System for Human Tissue Immuno-Oncology Profiling
CAMBRIDGE, Mass.--January 12, 2015--Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced that the company signed an agreement with Memorial Sloan Kettering (MSK) Cancer Center as part of Enumeral’s Phase II Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI). Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed at MSK in the laboratory of Jedd D. Wolchok, M.D., Ph.D.,... 
Printer Friendly Version
01/08/15Enumeral to Present at Upcoming Conferences in January
Cambridge, Mass.--January 8, 2015--Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present at the following conferences:Biotech Showcase™ 2015 at the Parc 55 Wyndham in San Francisco, on Wednesday, January 14 at 2:30 p.m. PST in Room Mission I.Noble Financial Capital Markets’ Eleventh Annual Equity Conference at Club Med Sandpiper Bay in Port St. Lucie, Florida, on Monday, January 19, at ... 
Printer Friendly Version